The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

People on statin therapy to lower their cholesterol may derive an additional benefit if they undergo intraocular surgery to repair a retinal detachment caused by a retinal tear: a slightly lower risk ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, highlights data presented at Retina Subspecialty Day.

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

A new study in mice shows that briefly anesthetizing the retina of the weaker eye can restore its neural influence in the adult visual cortex.

A new study in The New England Journal of Medicine revealed that the PRIMA brain computer interface (BCI) retinal implant helped people with advanced age-related macular degeneration regain some ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Here's how to know if either is right for you. Everyone wants smooth, bright, plump skin, a complexion that reflects the efforts you've made to take charge of your health and be proactive about ...

A newclinical trial is testing a retinal chip and AI-powered glasses to help patients see again after losing their central vision to eye disease. Eleven shots fired at Brown Mogotsi’s vehicle, no ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...